Strategic partnerships Scarab Genomics has recent exclusive licensing and distribution partnerships with Bionova Scientific and World Fusion, signaling openness to channel-driven growth and potential collaborator-led sales opportunities in CDMO services and international markets.

Production capabilities The Clean Genome engineered E. coli platform paired with the C-Flow continuous fermentation system offers high stability and yields, presenting a compelling value proposition for contract manufacturers, biotech partners, and scale-up opportunities seeking reliable microbial production.

Vaccine and biologics focus Historically targeting vaccines and biologics production with reduced-genome E. coli strains creates upsell potential for customers in vaccine programs and therapeutic protein manufacturing seeking safer, efficient cell factories.

Funding and growth Revenue in the low-to-mid single digits suggests a growth-ready profile that can be accelerated through enterprise partnerships, joint development projects, or pilot programs with larger biotech players looking for innovative production platforms.

Market expansion With a global distributor partner for Japan and ongoing collaborations, there are sales avenues for regional OEM/distribution deals, technical support packages, and localized validation studies to accelerate market entry for Scarab’s Clean Genome solutions.